Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 197.62

+0.1%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jayhawk969 who wrote (26643)	11/21/1998 3:06:00 PM
From: Cheryl Galt	Read Replies (2) of 32384

> What was the risk from Seragen's view point? Was the date of manufacture explicit? Or does the mention refer to an accounting item? < No. The date of the Octak manufacture is not explicit. The 10Q for the 3rd quarter states an action and its risk: In preparation for the approval by the FDA, if received, Seragen has manufactured commercial quantities of ONTAK(TM) and in purchase accounting for the Merger the Company has capitalized approximately $1.5 million of work-in-process inventory as of September 30, 1998. If the FDA does not approve the BLA, and ONTAK(TM) is not approved for commercial sale, any capitalized costs related to ONTAK(TM) will be expensed. Since Seragen received the BLA letter that mentioned "deficiencies" in the second quarter (on June 2nd or 3rd), and since the 10K for 2Q says nothing about any capitalized Ontak inventory, I inferred from the 3Q 10K that Seragen must have started manufacturing Ontak after seeing the BLA letter. They surely would not have presumed to start commercial manufacturing before the committee's June 2nd decision. (I hope.) The wording in the 3Q 10Q sounds to me like a calculated risk they were comfortable taking during 3Q, even after seeing the "deficiencies" comments in the June 2nd letter from FDA. Did I jump to an unfounded conclusion? Am I grabbing at straws? As Celery says, we're waiting for FDA's response to this, with no date limit. (It's Panretin that has the Nov 25 response limit.) I wish this 5-month-simmering watchpot would boil. Back to our vigil ... Perhaps we should light a candle. ;-] Although, perhaps this is the type of drama we need to "surprise" the market with the eventual good news. Am I grabbing at multiple straws? Cheryl

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next